Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportPoster - PhysicianPharm

Efficacy and safety of Lutetium-177 PSMA radioligand therapy versus Docetaxel in metastatic castration resistant prostate cancer - preliminary results of a randomized controlled trial

Swayamjeet Satapathy, Bhagwant Mittal, Ashwani Sood and Anish Bhattacharya
Journal of Nuclear Medicine May 2021, 62 (supplement 1) 1311;
Swayamjeet Satapathy
1Nuclear Medicine Postgraduate Institute of Medical Education & Research, Chandigarh Chandigarh India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bhagwant Mittal
1Nuclear Medicine Postgraduate Institute of Medical Education & Research, Chandigarh Chandigarh India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ashwani Sood
1Nuclear Medicine Postgraduate Institute of Medical Education & Research, Chandigarh Chandigarh India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anish Bhattacharya
1Nuclear Medicine Postgraduate Institute of Medical Education & Research, Chandigarh Chandigarh India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Abstract

1311

Objectives: Lutetium-177 prostate specific membrane antigen (177Lu-PSMA) based radioligand therapy (RLT) as salvage/ compassionate therapy in end stage metastatic castration resistant prostate cancer (mCRPC) has reported favourable biochemical and radiological responses. In this study, we aimed to prospectively compare the therapeutic efficacy and safety of 177Lu-PSMA-617 and Docetaxel.

Methods: Chemotherapy-naive patients with mCRPC and high PSMA expressing lesions on 68Ga-PSMA-11 PET/CT were randomly assigned to 177Lu-PSMA-617 (6-7.4 GBq per cycle, every 8 weeks, up to 4 cycles) or Docetaxel (75 mg/m2 per cycle, every 3 weeks, up to 10 cycles). The primary end-point was best PSA response rate defined as the proportion of patients achieving a ≥50% decline in PSA from baseline. Secondary end-points included radiological response, molecular response, progression-free survival (PFS) and safety profile.

Results: Twenty men with mCRPC, who had not received prior chemotherapy, were randomized to receive 177Lu-PSMA-617 or Docetaxel. Ten patients received a median cumulative dose of 15 GBq (range 6-24 GBq) of 177Lu-PSMA-617 over 1-4 cycles at intervals of 8-16 weeks while another ten patients were administered 5-10 cycles of Docetaxel at a dose of 75 mg/m2 every 3 weeks. The primary end point, i.e. the best PSA response was achieved in 6/10 (60%, 95% CI: 31.3%-83.2%) patients in the 177Lu-PSMA arm compared to 5/10 (50%, 95% CI: 23.7%-76.3%) patients in the Docetaxel arm (p=1.00). According to RECIST 1.1, the best objective response rate was 60% (95% CI: 23.1%-88.2%) in the 177Lu-PSMA arm versus 40% (95% CI: 16.8%-68.7%) in the Docetaxel arm (p=0.61). Further, as per the adapted PERCIST 1.0, the best molecular response rates, in the 177Lu-PSMA and Docetaxel arms, were 50% (95% CI: 18.8%-81.2%) and 40% (95% CI: 16.8%-68.7%) respectively (p=1.00). The median PFS in the 177Lu-PSMA and Docetaxel arms were 3.5 months and 4.0 months respectively (p=0.60). Of the treatment-related adverse events, grade 3 diarrhoea, palmar-plantar erythrodysesthesia syndrome, dyspnea, anaemia and febrile neutropenia were observed in one (10%) patient each in the Docetaxel arm with two (20%) patients requiring dose interruption/ reduction. In contrast, one patient (10%) in the 177Lu-PSMA arm experienced grade 4 thrombocytopenia.

Conclusions: With its relatively high safety margin and comparable therapeutic efficacy to that of Docetaxel, 177Lu-PSMA has a definite role in the management of mCRPC and could also be potentially employed in the first-line or second-line setting, rather than being solely reserved for advanced end-stage disease after exhausting all other treatment options.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 62, Issue supplement 1
May 1, 2021
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Efficacy and safety of Lutetium-177 PSMA radioligand therapy versus Docetaxel in metastatic castration resistant prostate cancer - preliminary results of a randomized controlled trial
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Efficacy and safety of Lutetium-177 PSMA radioligand therapy versus Docetaxel in metastatic castration resistant prostate cancer - preliminary results of a randomized controlled trial
Swayamjeet Satapathy, Bhagwant Mittal, Ashwani Sood, Anish Bhattacharya
Journal of Nuclear Medicine May 2021, 62 (supplement 1) 1311;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Efficacy and safety of Lutetium-177 PSMA radioligand therapy versus Docetaxel in metastatic castration resistant prostate cancer - preliminary results of a randomized controlled trial
Swayamjeet Satapathy, Bhagwant Mittal, Ashwani Sood, Anish Bhattacharya
Journal of Nuclear Medicine May 2021, 62 (supplement 1) 1311;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Poster - PhysicianPharm

  • Preliminary result of Texture Analysis on prediction of overall outcome of neuroendocrine tumors based on pre-therapy heterogeneity of somatostatin receptors on 68Ga Dotatate PET/CT scans.
  • Artificial Intelligence based segmental quantification of pulmonary perfusion for pre-transplant workup.
  • Comparison of stress myocardial Flow Response using regadenoson and dipyridamole in SPECT
Show more Poster - PhysicianPharm

Prostate/GU

  • 177Lu-PSMA-617 versus Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer: a randomised, open-label, phase 2 trial (TheraP)
  • Comparative Diagnostic Value Between 18F-FDG and 18F-DCFPyL PET/CT in Recurrent or Metastasis Clear Cell Renal Carcinoma after Nephrectomy
  • Test-Retest Reproducibility of Conventional Quantitative Parameters on PSMA-targeted 18F-DCFPyL PET/CT in Patients with Metastatic Prostate Cancer
Show more Prostate/GU

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire